Novel COL4A1-VEGFD gene fusion in myofibroma.
Guillaume DachySylvie FraitagBoutaina BoulouadnineSabine CordiJean-Baptiste DemoulinPublished in: Journal of cellular and molecular medicine (2021)
Myofibroma is a benign pericytic tumour affecting young children. The presence of multicentric myofibromas defines infantile myofibromatosis (IMF), which is a life-threatening condition when associated with visceral involvement. The disease pathophysiology remains poorly characterized. In this study, we performed deep RNA sequencing on eight myofibroma samples, including two from patients with IMF. We identified five different in-frame gene fusions in six patients, including three previously described fusion transcripts, SRF-CITED1, SRF-ICA1L and MTCH2-FNBP4, and a fusion of unknown significance, FN1-TIMP1. We found a novel COL4A1-VEGFD gene fusion in two cases, one of which also carried a PDGFRB mutation. We observed a robust expression of VEGFD by immunofluorescence on the corresponding tumour sections. Finally, we showed that the COL4A1-VEGFD chimeric protein was processed to mature VEGFD growth factor by proteases, such as the FURIN proprotein convertase. In conclusion, our results unravel a new recurrent gene fusion that leads to VEGFD production under the control of the COL4A1 gene promoter in myofibroma. This fusion is highly reminiscent of the COL1A1-PDGFB oncogene associated with dermatofibrosarcoma protuberans. This work has implications for the diagnosis and, possibly, the treatment of a subset of myofibromas.
Keyphrases
- genome wide
- growth factor
- copy number
- genome wide identification
- end stage renal disease
- dna methylation
- chronic kidney disease
- gene expression
- ejection fraction
- single cell
- type diabetes
- prognostic factors
- mesenchymal stem cells
- metabolic syndrome
- stem cells
- newly diagnosed
- transcription factor
- skeletal muscle
- amino acid
- smoking cessation